Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results from Phase 3 Trials at American Psychiatric Association Annual Meeting
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American Psychiatric Association (APA) Annual Meeting scheduled May 5-9, 2012 in Philadelphia, PA. Data on cariprazine, an investigational antipsychotic agent, includes additional details from a Phase III trial for acute mania in bipolar I disorder and results from an open-label extension study in schizophrenia. Separately, data on levomilnacipran, an investigational agent for the treatment of adults with major depressive disorder (MDD), includes additional analyses of Phase III trial results.